Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Do Antibiotics Cause Obesity Through Long-term Alterations in the Gut Microbiome? A Review of Current Evidence
Natalia G. Vallianou, Μaria Dalamaga, Theodora Stratigou, et al.
Current Obesity Reports (2021) Vol. 10, Iss. 3, pp. 244-262
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives
Natalia G. Vallianou, Gerasimos Socrates Christodoulatos, Ιrene Karampela, et al.
Biomolecules (2021) Vol. 12, Iss. 1, pp. 56-56
Open Access | Times Cited: 178
Mulberry Anthocyanins Ameliorate DSS-Induced Ulcerative Colitis by Improving Intestinal Barrier Function and Modulating Gut Microbiota
Jianling Mo, Jingdan Ni, Ming Zhang, et al.
Antioxidants (2022) Vol. 11, Iss. 9, pp. 1674-1674
Open Access | Times Cited: 74
The Role of Next-Generation Probiotics in Obesity and Obesity-Associated Disorders: Current Knowledge and Future Perspectives
Natalia G. Vallianou, Dimitris Kounatidis, Dimitrios Tsilingiris, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6755-6755
Open Access | Times Cited: 65
Polystyrene microplastics induce size-dependent multi-organ damage in mice: Insights into gut microbiota and fecal metabolites
Zhu Zhang, Wenqing Chen, Hiutung Chan, et al.
Journal of Hazardous Materials (2023) Vol. 461, pp. 132503-132503
Closed Access | Times Cited: 56
The Impact of Cesarean Section Delivery on Intestinal Microbiota: Mechanisms, Consequences, and Perspectives—A Systematic Review
Francesco Inchingolo, Alessio Danilo Inchingolo, Irene Palumbo, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1055-1055
Open Access | Times Cited: 18
Mycobiome and Cancer: What Is the Evidence?
Natalia G. Vallianou, Dimitris Kounatidis, Gerasimos Socrates Christodoulatos, et al.
Cancers (2021) Vol. 13, Iss. 13, pp. 3149-3149
Open Access | Times Cited: 63
Laboratory Findings and Biomarkers in Long COVID: What Do We Know So Far? Insights into Epidemiology, Pathogenesis, Therapeutic Perspectives and Challenges
Dimitrios Tsilingiris, Natalia G. Vallianou, Ιrene Karampela, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10458-10458
Open Access | Times Cited: 31
The potential of short-chain fatty acid epigenetic regulation in chronic low-grade inflammation and obesity
Julia Kopczyńska, Magdalena Kowalczyk
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 14
Could Adverse Effects of Antibiotics Due to Their Use/Misuse Be Linked to Some Mechanisms Related to Nonalcoholic Fatty Liver Disease?
Giovanni Tarantino, Vincenzo Citro
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 1993-1993
Open Access | Times Cited: 10
Obesity-Related Chronic Kidney Disease: From Diagnosis to Treatment
Elena Avgoustou, Ilektra Tzivaki, Γεωργία Διαμαντοπούλου, et al.
Diagnostics (2025) Vol. 15, Iss. 2, pp. 169-169
Open Access | Times Cited: 1
The Case against Antibiotics and for Anti-Virulence Therapeutics
Julia A. Hotinger, Seth T. Morris, Aaron E. May
Microorganisms (2021) Vol. 9, Iss. 10, pp. 2049-2049
Open Access | Times Cited: 41
Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis
Ana María Gómez Pérez, P. Ruiz‐Limón, Jordi Salas‐Salvadó, et al.
Gut Microbes (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 20
Microbiome and immuno-metabolic dysregulation in patients with major depressive disorder with atypical clinical presentation
Alexander Refisch, Zümrüt Duygu Şen, Tilman E. Klassert, et al.
Neuropharmacology (2023) Vol. 235, pp. 109568-109568
Open Access | Times Cited: 18
Thirty Obesity Myths, Misunderstandings, and/or Oversimplifications: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
Harold Bays, Angela Golden, Justin Tondt
Obesity Pillars (2022) Vol. 3, pp. 100034-100034
Open Access | Times Cited: 26
Bariatric surgery, gastrointestinal hormones, and the microbiome: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
Bharti Shetye, Franchell Richard Hamilton, Harold Bays
Obesity Pillars (2022) Vol. 2, pp. 100015-100015
Open Access | Times Cited: 22
Microbiome Research in Greece: A Comprehensive Bibliometric Study
Christos Stefanis, Christina Tsigalou, Ioanna Bezirtzoglou, et al.
Microorganisms (2025) Vol. 13, Iss. 4, pp. 725-725
Open Access
Anti-inflammatory and gut microbiota regulatory effects of ultrasonic degraded polysaccharides from Auricularia auricula-judae in DSS-induced colitis mice
Tahidul Islam, Baojun Xu, Zhaoxiang Bian
Ultrasonics Sonochemistry (2025), pp. 107339-107339
Open Access
The impact of mass drug administration of antibiotics on the gut microbiota of target populations
Ethan Gough
Infectious Diseases of Poverty (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 20
The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity
Ioannis Lempesis, Jun‐Li Liu, Μaria Dalamaga
Metabolism Open (2022) Vol. 16, pp. 100220-100220
Open Access | Times Cited: 20
Applied physiology: gut microbiota and antimicrobial therapy
Andrey V. Suslov, Alin Panas, Mikhail Y. Sinelnikov, et al.
European Journal of Applied Physiology (2024) Vol. 124, Iss. 6, pp. 1631-1643
Closed Access | Times Cited: 4
Bilirubin bioconversion to urobilin in the gut-liver-kidney axis: A biomarker for insulin resistance in the Cardiovascular-Kidney-Metabolic (CKM) Syndrome
Zachary A. Kipp, Olufunto O. Badmus, David E. Stec, et al.
Metabolism (2024), pp. 156081-156081
Open Access | Times Cited: 4
Epigallocatechin-3-gallate attenuates the sulfamethoxazole-induced immunotoxicity and reduces SMZ residues in Procambarus clarkii
Yunchao Zhang, Qi Wang, Fei Zhu
Journal of Hazardous Materials (2024) Vol. 472, pp. 134602-134602
Closed Access | Times Cited: 3
Ethics and antibiotic resistance
Euzebiusz Jamrozik, George Heriot
British Medical Bulletin (2021) Vol. 141, Iss. 1, pp. 4-14
Open Access | Times Cited: 20
Impact of antibiotics on off-target infant gut microbiota and resistance genes in cohort studies
Rebecca M. Lebeaux, Juliette C. Madan, Quang P. Nguyen, et al.
Pediatric Research (2022) Vol. 92, Iss. 6, pp. 1757-1766
Open Access | Times Cited: 15
Could gut mycobiome play a role in NAFLD pathogenesis? Insights and therapeutic perspectives
Dimitrios Fotis, Junli Liu, Μaria Dalamaga
Metabolism Open (2022) Vol. 14, pp. 100178-100178
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top